Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis
- 1 September 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in European Journal of Gastroenterology & Hepatology
- Vol. 22 (9), 1085-1092
- https://doi.org/10.1097/meg.0b013e32833a4822
Abstract
Background The vasoconstrictor terlipressin is widely used in the treatment of the hepatorenal syndrome and variceal bleeding. However, terlipressin may compromise cardiac function and induce ischemia. Aim Therefore, we aimed to assess the effects of terlipressin on cardiac function and perfusion. Methods Twenty-four patients with cirrhosis and ascites participated, including nine with refractory ascites. Gated myocardial perfusion imaging, mean arterial blood pressure (MAP), cardiac output (CO), ejection fraction (EF), end-diastolic volume (EDV), perfusion, and motion of the myocardium were determined before and after a bolus injection of 2mg terlipressin. Results MAP increased after terlipressin (P value of less than 0.001). EF and CO fell by -16 and -17%, respectively in the terlipressin group versus 1 and -2%, respectively in the placebo group (P value of less than 0.001 and P value of less than 0.01). In the terlipressin group, EDV increased by 18 versus -4% in the placebo group (P value of less than 0.01). Wall motion in the anterior and posterior walls fell by -18 and -22%, respectively after terlipressin treatment versus 0 and 0% in the placebo group (P value of less than 0.01). In contrast, myocardial perfusion and stroke volume were unaltered in both the groups. The change in EF during terlipressin treatment correlated significantly with the change in MAP (r=-0.60, P value < 0.002). Patients with refractory ascites had a higher EF and lower EDV and ESV than the patients with nonrefractory ascites, both at baseline and after terlipressin treatment. The decrease in the left ventricular wall thickening and wall motion correlated with the Child-Pugh score, r=-0.59, P=0.005 and r=-0.48, P=0.03. Conclusion In advanced cirrhosis, the increase in afterload and EDV after terlipressin treatment result in a decrease in left ventricular wall motion, resulting in reduced CO and EF, but myocardial perfusion is preserved. Alteration in cardiac function at baseline and after terlipressin treatment relates to the stage of decompensation. Eur J Gastroenterol Hepatol 22: 1085-1092 (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.Keywords
This publication has 42 references indexed in Scilit:
- Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndromeAdvances in Therapy, 2008
- “Terlipressin in the treatment of septic shock: the earlier the better?”Best Practice & Research Clinical Anaesthesiology, 2008
- Vasopressin: Mechanisms of action on the vasculature in health and in septic shockCritical Care Medicine, 2007
- The use of vasoconstrictors in patients with cirrhosis: Type 1 HRS and beyondHepatology, 2006
- Comparative Cardiac Effects of Terlipressin, Vasopressin, and Norepinephrine on an Isolated Perfused Rabbit HeartAnesthesiology, 2005
- Terlipressin-Related Acute Myocardial Infarction: A Case Report and Literature ReviewThe Kaohsiung Journal of Medical Sciences, 2004
- Central and systemic haemodynamic effects of terlipressin in portal hypertensive patientsLiver International, 2000
- Cloning, Functional Expression and Tissue Distribution of Human cDNA for the Vascular-Type Vasopressin ReceptorBiochemical and Biophysical Research Communications, 1994
- Heat production of rat anococcygeus muscle during isometric contractionAmerican Journal of Physiology-Cell Physiology, 1988
- CONTROLLED TRIAL OF TERLIPRESSIN ('GLYPRESSIN') VERSUS VASOPRESSIN IN THE EARLY TREATMENT OF OESOPHAGEAL VARICESThe Lancet, 1982